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Regular Article
VASCULAR BIOLOGY
Interleukin-7 is produced by afferent lymphatic vessels and supports
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Key Points
• Afferent lymphatic vessels
express interleukin-7.
• Interleukin-7 supports
lymphatic drainage.
The cytokine interleukin (IL)-7 exerts essential roles in lymph node (LN) organogenesis
and lymphocyte development and homeostasis. Recent studies have identified lymphatic
endothelial cells (LECs) asamajorsourceof IL-7 inLNs.Here,we report that LECsnot only
produce IL-7, but alsoexpress the IL-7 receptor chains IL-7Ra andCD132.Stimulationwith
recombinant IL-7 enhanced LEC in vitro activity and induced lymphangiogenesis in the
corneaofwild-type (WT)mice.Whereas in IL-7Ra2/2mice, dermal lymphatic vessels (LVs)
were abnormally organized and lymphatic drainage was compromised, transgenic over-
expression of IL-7 inmice resulted in an expanded dermal LV networkwith increased drainage function.Moreover, systemic treatment
with recombinant IL-7 enhanced lymphatic drainage in theskinofWTmiceandofmicedevoidof lymphocytes.Experiments in IL-7Ra2/2
bone marrow chimeras demonstrated that the drainage-enhancing activity of IL-7 was exclusively dependent on IL-7Ra expression in
stromal but not in hematopoietic cells. Finally, near-infrared in vivo imaging performed in IL-7Ra2/2 mice revealed that the pumping
activity of collecting vessels was normal but fluid uptake into lymphatic capillaries was defective. Overall, our data point toward an
unexpected new role for IL-7 as a potential autocrine mediator of lymphatic drainage. (Blood. 2013;122(13):2271-2281)
Introduction
The lymphatic vascular system plays an essential role in tissue fluid
homeostasis by absorbing fluid from the interstitium and returning it
to the blood circulation.1 Lymphatic vessels (LVs) in tissues begin as
blind-ended capillaries, which give rise to larger collecting vessels
that eventually merge and connect with draining lymph nodes (LNs).
In contrast to the absorbing initial lymphatic capillaries, collecting
LVs are less permeable, contain valves, and are surrounded by a
continuous basementmembrane and a smoothmuscle cell layer.2 The
functional units of collecting LVs are the lymphangions, which span
between valves and spontaneously contract to propagate lymph and
lymph-borne cells.1 Besides their role in fluid homeostasis, LVs
are highly important for immune function. Whereas afferent LVs
mediate the transport of soluble antigen and the migration of leu-
kocytes to draining LNs, efferent LVs contribute to immune sur-
veillance by enabling lymphocyte recirculation between secondary
lymphoid organs and the blood.3 The intimate connection between
the lymphatic vascular system and the immune system is also re-
flected by the fact that many cytokines that act on immune cells
impact lymphatic endothelial cell (LEC) biology. For example,
tumor necrosis factor-a upregulates adhesion molecules and
inflammatory chemokines in LECs,4,5 whereas lymphotoxin6,7 and
interleukin (IL)-178 have been linked with inflammation-induced
lymphangiogenesis. By contrast, interferon-g9 and transforminggrowth
factor-b10 reportedly exert antilymphangiogenic activity.
IL-7 is a homeostatic cytokine produced by stromal cells in
primary and secondary lymphoid organs and also by keratinocytes,
hepatocytes, and intestinal epithelial cells.11,12 Recent reports have
shown that besides fibroblastic reticular cells, LN-resident LECs are
important producers of IL-7.13-16 IL-7 signals through a heterodimeric
receptor composed of the IL-7 receptor a chain (IL-7Ra or CD127)
and the cytokine receptor common g chain (CD132). IL-7 is essential
for T- and B-lymphocyte development and supports the survival and
homeostatic proliferation of naive and memory T cells.12,17 Further-
more, IL-7 plays a central role in LN organogenesis by regulating the
activity and number of lymphoid tissue inducer (LTi) cells.12,18,19
Mice with defects in IL-7 signaling are characterized by a striking
reduction in LN number and LN cellularity.20,21 Because of the cyto-
kine’s immune-boosting effects, which are mainly attributed to its
antiapoptotic and proliferation-inducing activity inT cells, IL-7 therapy
is currently under clinical evaluation for the treatment of various forms
of cancer and chronic viral infections.12
In a microarray study performed on LECs isolated from murine
skin, we have recently observed thatmessages encoding IL-7, IL-7Ra,
and CD132 were present in LECs,5 prompting us to further study the
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role of these genes in LEC biology. Here, we report that IL-7 and its
receptor chains are expressed at the protein level in LECs. In vitro,
exogenous as well as endogenous IL-7 supported biologic processes
such as LEC tube formation and migration. In vivo, experiments per-
formed in various mouse models, including bone marrow (BM)
chimeras, consistently documented the importance of IL-7 and IL-7Ra
expression in stromal cells in shaping LV morphology and in sup-
porting lymphatic drainage. Overall, our data point toward an auto-
crine role for IL-7 in the lymphatic vascular system and thus provide
novel functional significance for the expression of IL-7 in LECs.
Materials and methods
Cell culture
Human LECs and blood vascular endothelial cells (BECs) were isolated from
neonatal human foreskins as previously described.22 Cells were cultured
on plates coated with collagen type I (Advanced BioMatrix, Poway, CA;
3.1 mg/mL) and/or fibronectin (Millipore, Billerica, MA; 1 mg/mL) in
endothelial basal medium (Lonza, Walkersville, MD) supplemented with
20% fetal bovine serum (GIBCO, Paisley, UK), antibiotic antimycotic solution
(13; Fluka, Buchs, Switzerland), L-glutamine (2 mM; Fluka), hydrocortisone
(10 mg/mL; Fluka), and N,629-O-dibutyryladenosine 39,59-cyclic mono-
phosphate sodium salt (2.53 1022 mg/mL; Fluka). All cells were cultured
at 37°C in presence of 5% CO2.
Mice
C57BL/6 mice were from Charles River Laboratories (Sulzbach, Germany),
and RAG12/2 and BALB/c mice were from The Jackson Laboratories (Bar
Harbor, ME). IL-7Ra2/2mice18,20 as well as IL-7 transgenic mice expressing
murine IL-7 in all cell types23 have been previously described. IL-7-CrexR26-
enhanced yellow fluorescent protein (EYFP)mice16 were generated by crossing
BAC-transgenic IL-7Cre mice24 (kindly provided by Ellen Richie, M. D.
Anderson Cancer Center, Houston, TX) with R26-EYFP reporter mice.25
All experiments were approved by the Cantonal Veterinary Offices of
Zurich and St. Gallen or by the Animal Care and Use Committee of the
University of California, Berkeley.
Fluorescence-activated cell sorter (FACS) analysis
Mouse ear skin or LNs were digested with collagenase IV (Invitrogen, Basel,
Switzerland) as previously described.26 Single-cell suspensions were stained
with anti-mouse CD31-APC, anti-mouse CD45-PerCP (both from Biolegend,
San Diego, CA), hamster anti-mouse podoplanin (clone 8.1.1., Developmental
Studies Hybridoma-Bank, University of Iowa, IA), and anti-hamster-PE (In-
vitrogen) or anti-hamster-Alexa 488 (Invitrogen). The expression of IL-7Ra
and CD132 was detected by additionally staining with anti-mouse CD127-
FITC (Biolegend), anti-mouse CD132-biotin (eBioscience, San Diego, CA),
and streptavidin-Alexa 488 (Invitrogen). IL-7 expression in vivo was analyzed
by measuring yellow fluorescent protein (YFP) in ear tissue of IL-7-CrexR26-
enhance YFP (EYFP) mice.16 FACS data were acquired on a BD FACSCanto
(BD Biosciences, Allschwil, Switzerland) using FACSDiva software (BD
Biosciences). Data were analyzed offline using FlowJo software (Treestar,
Ashland, TN).
In vivo systemic treatment with IL-7/anti–IL-7 complexes
Recombinant human IL-7 (eBioscience) was mixed with the anti-human IL-7
monoclonal antibody clone M25 (NCI BRB Preclinical Repository, Rockville,
MD), as previously described.27 Mice received intraperitoneal injections of 1.5
mg of IL-7/anti–IL-7 complexes every other day for a total of 7 days.
Immunofluorescence analysis of ear whole mounts
Mice were sacrificed and ears harvested after depilation. Ears were split
into 2 halves along the cartilage and fixed with 4% paraformaldehyde for
2 hours. Ears werewashedwith phosphate-buffered saline (PBS) and incubated
for 2 hours in PBS containing 12% bovine serum albumin, followed by
overnight incubations with rabbit anti-mouse lymphatic vessel endothelial
hyaluronan receptor (LYVE)-1, rat anti-mouse CD31 (BD Biosciences), or
rabbit-anti-YFP (Clontech, Basel, Switzerland). After PBS washes, ears
were incubated for.4 hours with Alexa-conjugated secondary antibodies
(all from Invitrogen). Ears were washed in PBS and fixed for 10 minutes
with 4% paraformaldehyde. Samples were mounted using Vectashield
mounting medium (Vector Laboratories, Burlingame, MA) and analyzed
on an Zeiss LSM 710-FCS confocal microscope using a 10 3 0.3 NA EC
Plan-Neofluar and a 20 3 0.8 NA Plan-Apochromat objective (Zeiss AG,
Goettingen, Germany). Images were acquired using Zeiss ZEN 2009 software
(Carl Zeiss AG) and processed using Imaris software (version 7.1.1; Bitplane,
Zu¨rich, Switzerland).
Computer-assisted analyses of ear whole mounts
Images of 3 randomly chosen fields of view from LYVE-1–stained whole
mount samples were acquired. Computer-assisted image analysis, including
the total LV length and the distance between branching points, was performed
using ImageJ. The total area covered by LVs was determined using an area-
calculating tool. The average vessel diameter was calculated by dividing the
lymphatic surface area with the LV length. The number of branching points
was quantified manually.
Lymph flow assessment using Evans blue dye
A total of 3mLof Evans blue dye (Fluka, 10mg/mL in PBS)were injected into
the ear of anesthetized mice using a Hamilton syringe. Sixteen hours later,
mice were anesthetized and pictures of the ears were taken using a Canon
DS126191 camera. Subsequently, mice were sacrificed and Evans blue dye
was extracted from the ears by incubation for 3 days in formamide (Fluka) at
room temperature. The background-subtracted absorbance was measured on
an Infinite M200 microplate reader by measuring the wavelength at 620 and
740 nm. The concentration of dye in the extracts was calculated using a
standard curve of Evans blue in formamide.
BM chimeras
WT or IL-7Ra2/2 mice were lethally irradiated (950 rad), reconstituted with
5 3 106 BM cells from either genotype and used in experiments at least
8 weeks after irradiation.
Statistical analysis
Normally distributed datawere analyzed using the Student’s t test. Not normally
distributed data sets were analyzed using the Mann-Whitney test. Results are
presented as mean 6 standard error of the mean (SEM). Differences were
considered statistically significant when P, .05. Significant outliers, identified
by Grubb’s test, were excluded. Statistical analysis was performed with Prism
5 (GraphPad, La Jolla, CA).
See supplemental Data on the Blood Web site for quantitative real-time
polymerase chain reaction (qPCR) and functional LEC in vitro assays used
in this work. See supplemental Material for corneal micropocket assays and
near-infrared lymphatic imaging used in this work.
Results
IL-7 and its receptor chains are expressed by LECs in vivo
To study the in vivo expression of IL-7 and its receptor chains, LECs
and BECs were FACS-sorted from murine ear skin single-cell sus-
pensions (Figure 1A), followed bymessengerRNA(mRNA) isolation,
generation of amplified complementary DNA, and qPCR analysis.5 In
this analysis, messages encoding IL-7 and CD132 were considerably
higher expressed in LECs comparedwithBECs; IL-7RamRNA levels
were also slightly increased in LECs over BECs (Figure 1B). FACS
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Figure 1. IL-7 and its receptor chains are expressed in LECs in vivo. (A-B) FACS sorting was used to isolate LECs and BECs from single-cell suspensions generated from
enzymatically digested mouse ear skin. qPCR was performed on the extracted, reversely transcribed and amplified complementary DNA material. (A) Depiction of the gating
scheme used to isolate BECs (CD452CD311podoplanin2) and LECs (CD452CD311podoplanin1). (B) qPCR analysis revealed that IL-7 and its receptor chains were more
highly expressed in LECs compared with BECs. Pooled data from 3 experiments are shown. (C-E) To validate the expression of candidate genes in LECs (gated on CD452
CD311podoplanin1 cells) and BECs (gated on CD452CD311podoplanin2 cells) at the protein level, FACS analysis was performed on ear and brachial LN single-cell
suspensions. (C) CD132 was preferentially expressed in LECs compared with BECs, whereas (D) IL-7Ra was similarly expressed in LECs and BECs. (E) No expression of IL-
7Ra was detected when performing FACS analysis on ear skin and LN single-cell suspensions from IL-7Ra2/2 mice. Representative plots from 3 different experiments are
shown. (F) FACS analysis performed on single-cell suspensions generated from the ears of IL-7-CrexR26-EYFP mice confirmed YFP expression in most LECs (gated on
CD452CD311podoplanin1), but not in BECs (gated on CD452CD311podoplanin2). Representative FACS plots showing YFP expression in LECs and BECs are shown. (G) A
summary of the percentages of YFP-expressing LECs and BECs from all experiments (n 5 3) is shown. (H-I) Confocal laser scanning microscopic analysis of ear skin whole
mounts prepared from IL-7-CrexR26-EYFP mice detected YFP expression in virtually all LYVE-11 LVs (H), but not in MECA-321 blood vessels (I). Scale bar represents 100 mm.
**P , .01.
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Figure 2. IL-7 activates LEC in vitro function and induces lymphangiogenesis in vivo. (A-G) Functional in vitro assays were performed to analyze the effect of IL-7 on
LECs. (A) Overnight treatment with IL-7 significantly enhanced LEC adhesion to fibronectin-coated plates. This response could be reversed by concomitant treatment with
CD132 or IL-7Ra blocking antibodies. Notably, the IL-7–induced response was comparable to the one induced by treatment with VEGF-A (positive control). (B) Overnight
treatment of LECs with IL-7 led to an upregulation of the fibronectin-binding integrin a5b1, as seen in FACS. Data from 1 of 4 similar experiments are shown. (C-D) Tube
formation assays were performed by covering confluent LEC monolayers with collagen type I containing IL-7 (50 ng/mL). (C) Representative images showing the IL-7–induced
increase in LEC tube formation. (D) IL-7–induced tube formation could be reversed when performing the assay in presence of CD132 or IL-7Ra blocking antibodies. (E-G)
Effect of siRNA-mediated knockdown of IL-7 in LECs. (E) Transfection with siRNA significantly reduced IL-7 mRNA levels in LECs (E) as well as the capacity of LECs (F) to
form tube-like structures. (G) Moreover, knockdown of IL-7 levels in LECs reduced LEC migration, as measured in a scratch-wound assay. Data from 1 of 3 similar
experiments are shown. (H-I) To analyze the effect of IL-7 on lymphangiogenesis in vivo, a cornea micropocket assay was performed. (H) Representative immunofluorescent
micrographs demonstrating ingrowth of new LVs into the cornea 14 days after IL-7 pellet implantation. LYVE-1: red. Scale bar represents 50 mm. (I) A significant difference
was observed in the area covered by lymphatics between the treatment and the control group (n 5 9 mice per group). *P , .05; **P , .01; ***P , .001. ctr, control; IgG,
immunoglobulin G.
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analysis performed on ear skin and LN single-cell suspensions con-
firmed higher expression of CD132 protein in LECs compared with
BECs (Figure 1C), whereas IL-7Ra protein levels were comparable
(Figure 1D). Importantly, no signal for IL-7Ra was detected when
analyzing skin or brachial LNLECs from IL-7Ra2/2mice (Figure 1E).
To further assess whether dermal LECs produce IL-7, we analyzed the
skin of IL-7-CrexR26-EYFPmice,16 which express EYFP in cells with
past or present IL-7 promoter activity.16 FACS analysis of ear skin
single-cell suspensions revealed that the majority of LECs but virtually
noBECswere EYFP1 (Figure 1F-G). Similarly, wholemount analyses
performed in the ear skin of IL-7-CrexR26-EYFPmice detected EYFP
expression in virtually all LYVE-11 LVs, but not in MECA321 blood
vessels (Figure 1H-I). IL-7 expression was also detected in in
vitro–cultured murine dermal LECs5 isolated from Immortomice28
(data not shown). In vitro–cultured murine dermal LEC supernatant
significantly enhanced the survival of murine CD41 T cells, and this
survival-enhancing activity was reduced upon addition of IL-7–
blocking antibody (supplemental Figure 1), indicating IL-7 bio-
activity. Notably, similar results were recently obtained for IL-7
derived from LN LECs.16 Overall, our findings revealed that murine
dermal LECs expressed both functional IL-7 and the IL-7 receptor
chains.
IL-7 activates LECs in vitro and induces lymphangiogenesis
in vivo
To further investigate the function of IL-7 and its receptor chains in
LECs, we performed in vitro studies with primary dermal human
LECs, which expressed detectable levels of IL-7, IL-7Ra, and
CD132 mRNA and protein (supplemental Figure 2). IL-7 was pre-
viously shown to induce lymphatic marker gene expression and tube
formation in a human endothelial cell line.29 To analyze whether
stimulation with exogenous IL-7 would induce similar cellular
responses in primary human LECs, functional assays were performed.
IL-7 treatment induced only weak proliferation in LECs (data not
shown), but led to a strong increase in LEC adhesion to fibronectin
(Figure 2A). This effect could be reversed by addition of antibodies
blocking CD132 or IL-7Ra and was comparable to the effect induced
by vascular endothelial growth factor-A (VEGF-A) treatment
(Figure 2A). Increased adhesion to fibronectin was paralleled by
an IL-7–induced upregulation of the fibronectin-binding integrin
a5b1
30 (Figure 2B). IL-7 treatment also induced a dose-dependent
increase in LEC migration in a scratch-wound assay (supplemen-
tal Figure 3A-B) and a striking upregulation of the lymphatic-specific
transcription factor Prox-131 (supplemental Figure 3C-F). Moreover,
stimulation with exogenous IL-7 significantly enhanced the ability
of cultured LECs to form tube-like structures in a collagen matrix
(Figure 2C-D). This process was reversed when performing the assay
in the presence of CD132- or IL-7Ra–blocking antibodies (Figure 2D).
Interestingly, small interfering RNA (siRNA)-mediated knockdown
of IL-7 in LECs significantly reduced LEC tube formation and mi-
gration (Figure 2E-G), suggesting an autocrine contribution of IL-7
to LEC biology. Although incubation of LECs with IL-7 only in-
duced weak phosphorylation of the signal transducer and activator of
transcription (Stat)5, a well-known mediator of IL-7 signaling in
hematopoietic cells,17 treatment with a Stat5-inhibitor completely
reverted IL-7–induced tube formation (supplemental Figure 3G-H).
To investigate the lymphangiogenic properties of IL-7 in vivo, a
mouse corneal micropocket assay was performed. For this, pellets
containing either IL-7 or vehicle control were surgically implanted
into the corneas of wild-type (WT) mice and the growth of vessels
toward the pellet was analyzed 14 days later by immunofluorescence.
IL-7–containing pellets induced a significant lymphangiogenic response
in the cornea (Figure 2H-I). In conclusion, our findings identified IL-7
as a potent inducer of lymphangiogenesis in vitro and in vivo.
Figure 3. TheLVnetwork and lymphatic drainage are
compromised in IL-7Ra2/2 mice. (A-E) The LYVE-11
lymphatic network in the ear skin of IL-7Ra2/2 and WT
control mice was analyzed in whole mount preparations.
(A) Representative images showing LYVE-11 LVs in the
ear skin of both genotypes. Scale bar represents 200mm.
(B-E) Image-based morphometric analysis revealed a
significant decrease (B) in average LYVE-11 vessel
diameter, whereas the average LYVE-11 area (C) was
increased in the ear skin of IL-7Ra2/2 compared with
WT mice. (D) The number of branching points was
significantly increased, whereas the (E) distance be-
tween branching points was decreased in IL-7Ra2/2
compared with WT mice. (F-G) To evaluate lymphatic
drainage function, Evans blue dye was intradermally
injected into the ears of IL-7Ra2/2 and WT mice, and
the dye content remaining in the ear was extracted and
quantified 16 hours later. (F) Quantification detected
increased Evans blue levels in the ears of IL-7Ra2/2
mice, indicative of defective lymphatic drainage. (G)
Representative pictures taken 16 hours after Evans
blue injection. Pooled data from 2 similar experiments
involving a total of 10 mice/group are shown. *P, .05;
**P , .01; ***P , .001.
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Impaired drainage function of dermal lymphatics in
IL-7Ra2/2 mice
We next analyzed the LV phenotype in IL-7Ra2/2 mice. Immuno-
fluorescent staining of ear skin whole mounts for the lymphatic
capillary marker LYVE-12 revealed striking differences in the orga-
nization of the LV network between IL-7Ra2/2 and WT mice
(Figure 3A). LV diameters were significantly reduced (Figure 3B)
and the lymphatic network in IL-7Ra2/2 mice was more dense, as
evidenced by an increase in the total area covered by LVs (Figure 3C),
a strong increase in the number of branching points (Figure 3D), and
a reduced distance between branching points (Figure 3E). To inves-
tigate whether these morphologic abnormalities had any functional
consequences, we performed lymphatic drainage experiments by in-
jecting small amounts of Evans blue into the ear pinna. Evans blue,
which rapidly binds albumin in situ, is specifically taken up by lym-
phatics upon intradermal injection.32,33 When analyzing the ears
16 hours after injection, approximately 2-fold more Evans blue
was retained in the ears of IL-7Ra2/2mice compared with WTmice
(Figure 3F-G), indicating decreased drainage function. Notably, when
performing the same experiment in K14-VEGFR3-Ig mice, which
completely lack dermal lymphatic capillaries and mount a severe
drainage phenotype,34 a 4.5-fold increase in Evans blue retention
in the ears was measured (supplemental Figure 4). Thus, the 2-fold
difference observed in IL-7Ra2/2mice, which still retain an—albeit
disorganized—dermal lymphatic capillary network (Figure 3A-E),
suggested a substantial defect in drainage.
Enhanced drainage function of the dermal lymphatics in
IL-7tg mice
Wenext assessed the lymphatic phenotype and function in transgenic
mice ubiquitously overexpressing IL-7 in all cells types (IL-7tg).23
Here, the diameters of dermal LVs as well as the area covered by
LVs were significantly increased in comparison with WT control
(Figure 4A-C). By contrast, the number of branching points was
similar, whereas the distance between branching points was reduced
in IL-7tg compared with WTmice (Figure 4D-E). Performing Evans
blue drainage experiments approximately 30% less dye was retained
in the ears of IL-7tg compared withWTmice 16 hours after injection
(Figure 4F-G). Thus, whereas loss of IL-7 receptor signaling reduced
lymphatic drainage (Figure 3F-G), transgenic overexpression of IL-7
had the opposite effect.
Systemic treatment with recombinant IL-7 enhances lymphatic
drainage in the skin
Our studies in IL-7Ra2/2 and IL-7tgmice indicated that IL-7 signaling
supported lymphatic drainage function. However, it remained unclear
whether the effects observed were caused by genotype-induced devel-
opmental differences in the lymphatic network or whether IL-7 re-
mained important for lymphatic drainage function in adulthood. To
address this question, adult WT mice were injected intraperitone-
ally for 7 days with recombinant IL-7 complexed with anti–IL-7
antibody (IL-7/anti–IL-7 complexes) (Figure 5A). IL-7/anti–IL-7 com-
plexes represent a well-documented method for boosting the in vivo
efficacy of IL-7, presumably by enhancing IL-7 pharmacokinetics and
half-life.18,27 Treatment with IL-7/anti–IL-7 complexes induced a
strong lymphoproliferative response in the spleen of WT mice (data
not shown). Drainage experiments revealed that complex treatment
significantly enhanced lymphatic clearance of Evans blue from the
injected ear (Figure 5B-C). IL-7/anti–IL-7 complex treatment also
enhanced dermal lymphatic drainage in RAG12/2 mice lacking T
and B lymphocytes (Figure 5D-E). Moreover, complex treatment
induced some subtle, near-significantmorphologic changes in dermal
LVs in WT and RAG12/2 mice (supplemental Figure 5). Thus,
Figure 4. The LV network is expanded and displays
enhanced drainage in the skin of IL-7 transgenic
mice. (A-E) The LYVE-11 lymphatic network in the ear
skin of transgenic mice expressing IL-7 in all cells
(IL-7tg) or in WT control mice was analyzed in whole
mount preparations. (A) Representative images showing
LYVE-11 LVs in the ear skin of both genotypes. Scale bar
represents 200 mm. (B-E) Image-based morphometric
analysis revealed that the average LV diameter (B) and
the average LYVE-11 area (C) were significantly in-
creased in ear skin of IL-7tg comparedwithWTmice. (D)
The number of branching points remained unchanged,
whereas the average distance between branching points
(E) was reduced in IL-7tg compared with WT mice. Re-
sults from 1 of 2 similar experiments are shown (n 5 4
mice/group). (F-G) To evaluate lymphatic drainage func-
tion, Evans blue dye was intradermally injected into the
ears of IL-7tg and WT mice and the dye content re-
maining in the ear was extracted and quantified 16 hours
later. (F) Quantification revealed reduced Evans blue
levels in the ears of IL-7tg mice, indicative of increased
lymphatic drainage. (G) Representative pictures taken
16 hours after Evans blue injection. Pooled data from
3 experiments involving a total of 15-18 mice/group are
shown. *P , .05; **P , .01; ***P , .001.
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administration of IL-7 in a therapy-like setting was capable of
enhancing LV drainage function in mice.
Normal lymphatic morphology and drainage depends on IL-7Ra
expression in stromal cells
The results obtained inRAG12/2mice demonstrated that the drainage-
enhancing activity of recombinant IL-7 did not depend on IL-7–
responsive T and B lymphocytes (Figure 5D-E). However, IL-7
also induces important biologic responses in other hematopoietic
cells, such as in LTi cells or dendritic cells.12,19 To further investigate
the contribution of hematopoietic vs stromal cell–expressed IL-7Ra
to the lymphatic phenotype and drainage function, BM chimeras
were generated. Interestingly, analysis of the ear thickness revealed
that the ears of IL-7Ra2/2 mice reconstituted with either WT or IL-
7Ra2/2 BM were significantly thicker compared with those of WT
mice reconstituted with either BM (supplemental Figure 6A). As
expected, the LN cellularity was reduced in BM chimeras recon-
stituted with IL-7Ra2/2 BM (Figure 6A). Moreover, whole mount
analysis performed in the diaphragm revealed that the abnormal
lymphatic phenotype observed in IL-7Ra2/2 mice (Figure 3A-E)
was recapitulated in BM chimeras with IL-7Ra2/2 stromal cells,
whereas loss of IL-7Ra in hematopoietic cells had no effect (supple-
mental Figure 6B-D). Finally, Evans blue experiments demonstrated
that drainage was significantly reduced in chimeras with IL-7Ra2/2
stromal cells, independent of whether mice had been reconstituted
with WT or IL-7Ra2/2 BM (Figure 6B; supplemental Figure 6E).
Conversely, no defect in drainage was observed inWTmice that had
been reconstituted with IL-7Ra2/2 BM compared with WT mice
reconstituted with WT BM (Figure 6B). Notably, the drainage pheno-
type observed in BM chimeras (Figure 6B) was less pronounced
than in IL-7Ra2/2 mice (Figure 3F-G), possibly because of general
irradiation-induced lymphatic dysfunction35 or the advanced age of
the chimeras. In line with our previous findings, treatment with IL-7/
anti–IL-7 complexes enhanced lymphatic drainage in BM chimeras
with functional IL-7Ra in stromal cells, irrespective of IL-7Ra ex-
pression in hematopoietic cells (Figure 6C-D). Notably, no enhance-
ment of drainage was observed in chimeras expressing IL-7Ra in
hematopoietic but not in stromal cells (Figure 6D). Thus, the drainage-
promoting activity of IL-7 was exclusively dependent on IL-7Ra
expression in stromal cells, suggesting a direct effect of IL-7 on LECs.
IL-7Ra2/2 mice display a defect in fluid uptake and transport in
lymphatic capillaries
To further investigate the mechanism of reduced lymphatic drainage
in IL-7Ra2/2 mice, near-infrared in vivo lymphatic imaging was
performed. To this end, a near-infrared lymphatic tracer was injected
into the hind paw and the lower limb was dynamically imaged under
a stereomicroscope. This analysis detected no significant difference
in themorphology or the pulse rates of the collectingLVs in IL-7Ra2/2
compared withWTmice (Figure 7A-C; supplemental Videos 1 and 2).
Instead, lymphatic dysfunction was observed at the level of the initial
lymphatic capillaries. Although tracer uptake was normal in mostWT
mice, with only deeper collecting vessels visible proximal to the injec-
tion site, themajority of IL-7Ra2/2mice displayed increased spreading
Figure 5. Systemic treatment with recombinant IL-7/
anti-IL-7 complexes equally enhances lymphatic
drainage in the skin or WT and of RAG12/2mice. (A)
WT and RAG12/2 mice were treated intraperitoneally
every other day for a total of 7 days with IL-7/anti–IL-7
complexes or PBS. On day 6, Evans blue dye was
injected intradermally into the ears of mice. Animals
were sacrificed on day 7 and ears were used for
Evans blue quantification. (B-C) IL-7/anti–IL-7 complex–
treated WT mice exhibited increased drainage function
of dermal LVs upon intradermal injection of Evans blue.
(B) Quantification of the total Evans blue dye present
in the ear 16 hours after injection. (C) Representative
pictures taken 16 hours after Evans blue injection.
(D-E) IL-7/anti–IL-7 complex–treated RAG12/2 mice
exhibited increased drainage function of dermal LVs
upon intradermal injection of Evans blue. (D) Quan-
tification of the total Evans blue dye present in the ear
16 hours after injection. (E) Representative pictures
taken 16 hours after Evans blue injection. Pooled data
from a total of 10 mice/group are shown. **P , .01.
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of the tracer through superficial initial lymphatic capillaries, with
evidence of leakage of the tracer into the interstitium (Figure 7D-E).
Discussion
In this paper, we have analyzed the biologic role of IL-7 in the
lymphatic system and identified a previously unknown activity of
this cytokine in promoting lymphatic drainage. Several studies have
recently described the expression of IL-7 by LECs in LNs.13-16 We
now report that LECs isolated from human or murine skin as well as
LECs also present in murine skin produce this cytokine. Together
with very recent data from IL-7 knock-in mice,15,36 our findings
indicate that LECs might be a source of IL-7 throughout the body.
Interestingly, we also detected IL-7 protein in human skin-draining
afferent lymph37 (supplemental Figure 7). However, given that IL-7
is also expressed bydermal keratinocytes (supplemental Figure 2),11,12
LECs are likely not the only source of IL-7 in skin-draining afferent
lymph. The IL-7 levels detected in lymph (15-35 pg/mL) were similar
to values detected in blood (supplemental Figure 7)38 and are in the
range of IL-7 concentrations shown to elicit biologic responses in
T cells in vitro.13,16 By contrast, the IL-7 concentrations required to
achieve biologic responses in cultured LECs where considerably
higher (.5 ng/mL). This indicates that lymph-borne IL-7 might
not primarily act in a paracrine manner on LECs. More likely,
LECs consume their self-synthesized IL-7, which likely reaches
much higher local concentrations in vicinity of the secreting cell.
Our hypothesis that IL-7 might act in an autocrine manner is also
supported by our in vitro findings demonstrating reduced tube
formation and migration upon siRNA-mediated knockdown of IL-7
in LECs. Moreover, treatment of RAG12/2 or BM chimeras with
IL-7/anti–IL-7 complexes demonstrated that the drainage-promoting
activity of IL-7 required IL-7Ra expression in stromal but not in
hematopoietic cells. The latter findings exclude any contribution of
IL-7–responsive lymphocytes or LTi cells to the drainage enhancing
activity of IL-7 and rather suggest a direct effect of IL-7 on IL-7
receptor-expressing LECs. Clearly, the ultimate proof of this new
concept of an autocrine role of IL-7 in LEC biology will require
further experiments in mice harboring an LEC-specific deletion of
IL-7 or IL-7Ra. In fact, the tools for generating such mice have
recently been generated.39-42
Figure 6. Intact lymphatic drainage and the drainage-promoting activity of IL-7 dependon IL-7Ra expression in stromal cells.BMchimeras betweenWTand IL-7Ra2/2
mice were generated and directly analyzed or subjected to IL-7/anti-IL-7 complex treatment. (A-B) Analysis of BM chimeras. (A) The LN cellularity was reduced in BM chimeras
reconstituted with IL-7Ra2/2 BM. Bars represent pooled data from 2 inguinal and 2 brachial LNs per mouse. (B) To evaluate lymphatic drainage function, Evans blue dye was
intradermally injected into the ears of BM chimeras and the dye content remaining in the ear was extracted and quantified 16 hours later. Quantification detected increasedEvans
blue levels in the ears of BM chimeraswith IL-7Ra2/2 stromal cells, indicative of defective lymphatic drainage. (C-D) Treatment of BM chimeraswith IL-7/anti-IL-7 complexes. (C)
IL-7/anti-IL-7 complex treatment led to a significant increase in the splenic cellularity of chimeras reconstituted with WT but not with IL-7Ra2/2 BM. (D) Evans blue drainage
experiments revealed that treatment of BM chimeras with IL-7/anti-IL-7 complexes only enhanced lymphatic drainage in chimeras with functional IL-7Ra in stromal cells
(WT→WT; IL-7Ra2/2→WT). Complex treatment of chimeras exclusively expressing IL-7Ra in hematopoietic cells but not in stromal cells (WT→ IL-7Ra2/2) did not improve
drainage. Pooled data from 1-2 experiments involving 4-6 mice/group are shown. *P , .05; **P , .01. n.s., not significant.
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Both transgenic overexpression of IL-7 and IL-7Ra deficiency
resulted in pronounced changes in the dermal lymphatic network in
mice. In IL-7Ra2/2mice, the dermal LVs were organized in a highly
branched, dense network of unusually thin LVs. Together with our in
vitro data demonstrating a role for IL-7 in LEC tube formation and
adhesion, the phenotype observed in IL-7Ra2/2 mice suggests that
IL-7 signaling might contribute to lymphangiogenesis by stabilizing
larger LVs. Notably, IL-7 had been previously linked with tumor
lymphangiogenesis and thought to act indirectly by upregulating
VEGF-D in IL-7R–expressing tumor cells.43,44 In light of our new in
vivofindings, it is likely that IL-7 also displays direct lymphangiogenic
activity on LECs in vivo, but we presently cannot exclude any indirect
contribution from IL-7 responsive hematopoietic cells, such as
T cells or LTi cells.
The most striking finding of our study was the observation that
IL-7 supported LV drainage function. Whereas LV drainage was
compromised in the skin of IL-7Ra2/2 mice, it was significantly
enhanced in IL-7tg mice. Moreover, treatment of mice with IL-7/
anti–IL-7 complexes over a relatively short period of 7 days sig-
nificantly enhanced lymphatic drainage. Intriguingly, drainage was
enhanced at this time point, despite only subtle visible changes in
the dermal LYVE-11 lymphatic capillary network. It is therefore
Figure 7. IL-7Ra deficiency does not affect the pumping activity of lymphatic collectors but impairs uptake and transport in lymphatic initials. IL-7Ra2/2 or WT
mice (n 5 7/genotype) were injected with a near-infrared dye (IRDye680) 20-kDa PEG conjugate into the hind paw and LVs in the upper and lower limb were examined under
a stereomicroscope. (A) Representative images of the collecting LVs in the lower limb of an IL-7Ra2/2 and a WT mouse. White circles indicate the region of the 2 collecting
vessels in which pulse rates were analyzed. (B) Representative plots of the pulse rates measured in the 2 collecting vessels of a WT and an IL-7Ra2/2 mouse. (C)
Quantification of the collecting LV contractility revealed no difference in pulse rates between IL-7Ra2/2 and WT mice (n 5 7 mice/genotype). (D) Representative images of
normal and dysfunctional lymph flow in the dorsal paw skin (upper limb) located proximal to the dye injection site. Under normal conditions (left), only deeper collecting vessels
filled with dye are visible. By contrast, lymphatic dysfunction (right) is characterized by increased dye spreading through the initial lymphatic capillaries with evidence of
leakage (white arrows). (E) Quantification of normal (white) and dysfunctional (black) lymphatic drainage in the dorsal paw skin proximal to the injection site (n 5 7 mice/
genotype). Scale bar represents 1 mm.
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likely that the supportive effect of IL-7 on lymphatic drainage is not
only a consequence of the morphologic, lymphangiogenesis-related
changes in the LV network, but that IL-7 also stimulates lymphatic
drainage in otherways.Our near-infrared imaging experiments clearly
showed that the deficiency in lymphatic drainage observed in absence
of IL-7Ra signaling was not due to defects in the morphology or the
pumping activity of lymphatic collecting vessels, but rather due to
impaired lymph uptake or transport in lymphatic capillaries. The
mechanism of lymph transport into initial lymphatic capillaries is
not completely understood.45 Uptake is thought to mainly involve
passive diffusion of fluids and macromolecules through the charac-
teristic open flaps (named primary valves) present between neighbor-
ing capillary LECs.46 However, evidence for additional active,
transcellular mechanisms has recently been reported.45 It is possible
that IL-7 promotes drainage by increasing the integrity of the lym-
phatic vascular wall or by regulating the distinct organization of
adhesion molecules and primary valves in lymphatic capillaries.46
Finally, the IL-7–induced upregulation of Prox-1 observed by us
(supplemental Figure 3) and others29 might contribute to enhanced
lymphatic drainage: analysis ofmice heterozygous forProx1 deletion
revealed that these mice had abnormalities in lymphatic flow and
displayed increased vascular leakage.47
IL-7 is currently under clinical evaluation for its ability to enhance
adaptive immunity in patients with viral infections or cancer. Thera-
peutic benefits of IL-7 treatment have mainly been attributed to drug-
induced improvement of T-cell survival, T-cell numbers, and T-cell
repertoire diversity.12 Our data suggest that IL-7 therapy could have
further beneficial, immune-activating effects by supporting lymphatic
drainage function and thereby increasing the transport of antigen to
draining LNs. On the other hand, our data also raise the concern
that IL-7 therapy in the context of cancer might enhance tumor
lymphangiogenesis and metastatic spread. Perhaps the most exciting
translational aspect of our study is its potential implications for the
treatment of LV dysfunction, namely lymphedema, for which only
limited treatment options currently exist.48 In fact, the only factor
with a broadly documented beneficial role in restoring LV function in
animal models of lymphedema is VEGF-C.48,49 Given our new data
on the pro-lymphangiogenic and drainage-promoting activity of IL-7,
this cytokine might be an interesting new candidate to evaluate in
future studies.
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